Home | Metabolism | Phenylketonuria (PKU) | Publications | Publication: Exploratory study of the effect of 1 week of orally-administered CNSA-001 (sepiapterin) on central nervous system (CNS) levels of tetrahydrobiopterin, dihydrobiopterin, and monoamine neurotransmitter metabolites in healthy volunteers

Publication: Exploratory study of the effect of 1 week of orally-administered CNSA-001 (sepiapterin) on central nervous system (CNS) levels of tetrahydrobiopterin, dihydrobiopterin, and monoamine neurotransmitter metabolites in healthy volunteers

Published in Molecular Genetics and Metabolism Reports, this research article presents the results of a study investigating the potential effects of CNSA-001 – a preparation of sepiapterin – on neurometabolites in the CNS 

  • Results from a Phase 1 exploratory study are presented in this publication. Concentrations of molecules involved in neurometabolic pathways were recorded at baseline and day 7 in 8 healthy subjects who were administered oral CNSA-001 (n=6) or placebo (n=2) over 7 days
  • Levels of metabolites of interest measured in cerebrospinal fluid and plasma in this study – BH4, BH2, homovanillic acid, and 5-hydroxyindoleacetic acid (5-HIAA) – are presented

Smith N, Longo N, Levert K, et al. Mol Genet Metab Rep. 2019;21:100500 

Once registered, you will be provided the DOI and PubMed links for this publication.

Sepiapterin is an investigational drug currently in development for PKU.

Register now to unlock the content

Register now to access the content on this page

Already registered?
If not, register below

Registration
  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

    *
    *
  • PTC will delete immediately the information provided if we cannot confirm you are a healthcare professional.
    Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any inquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

US-PKU-0205 | April 2023
Sign in or register to access exclusive content on this site 
  REGISTER

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
US-CORP-0330 | July 2022

COMING SOON

The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.